Within the past week, researchers announced the results of two major clinical trials that could herald a new era in cancer treatment. Scientists are learning how to teach the immune system to fight cancer and, potentially, prevent certain cancers from developing in the first place. Their discoveries also challenge the way the Food and Drug Administration (FDA) evaluates new medicines.
On November 17, Memorial Sloan Kettering Cancer Center announced that an experimental vaccine significantly prolonged survival in patients with acute myeloid leukemia (AML), a deadly cancer of the blood and bone marrow. Six days earlier, The New England Journal of Medicine published the results of a clinical trial demonstrating that a personalized messenger RNA (mRNA) vaccine reduced the likelihood that melanoma, a potentially deadly form of skin cancer, would recur after surgery.
Conventional vaccines train the immune system to recognize and attack invading organisms, such as viruses and bacteria. Cancer vaccines face a more complicated task: They must teach the immune system to distinguish the body’s own cancerous cells from healthy ones. Fortunately, cancer cells often produce abnormal proteins or unusually large quantities of normal proteins that the immune system can learn to recognize.
The leukemia vaccine galinpepimut-S contains laboratory-made peptides (short fragments of proteins) that mimic portions of a protein called Wilms tumor 1 (WT1). More than 95 percent of AML patients have leukemia cells that express this protein. The vaccine trains the immune system’s cancer-fighting T cells to recognize and attack leukemia cells that may have survived chemotherapy.
In a trial involving 126 patients whose leukemia had returned after treatment and who subsequently achieved another remission, researchers found that patients who received the vaccine survived a median of 24 months, compared with 14.7 months for those who received other available treatments. None of the patients qualified for a bone marrow transplant. The vaccine’s developer has yet to release the full trial data.
The melanoma vaccine takes a more personalized approach, using the same basic mRNA technology that scientists employed to develop COVID-19 vaccines.
Researchers analyze the DNA of a patient’s surgically removed tumor to identify mutations that cause cancer cells to produce distinctive proteins. They then manufacture a vaccine containing genetic instructions that tell some of the patient’s healthy cells to temporarily produce fragments of those proteins. The immune system learns to recognize these molecular fingerprints and attack any remaining cancer cells that carry them.
Moderna and Merck developed the vaccine, called intismeran, which can target up to 34 molecular fingerprints unique to an individual patient’s tumor. Researchers combined the vaccine with pembrolizumab (Keytruda), a drug that helps prevent cancer cells from disabling the immune system’s attack.
In a clinical trial involving 1,137 melanoma patients who had undergone surgery, 82.2 percent of those who received both the vaccine and pembrolizumab remained alive and cancer-free two years later, compared with 70 percent of those who received pembrolizumab alone.
Scientists at Johns Hopkins University are exploring whether vaccines might even prevent pancreatic cancer, one of the deadliest forms of cancer.
The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene provides instructions for making a protein that acts like a molecular switch, controlling signals that tell cells when to grow and divide. Certain mutations can jam that switch in the “on” position, encouraging uncontrolled cell growth. Uncontrolled cell growth and the ability of abnormal cells to invade surrounding tissues are hallmarks of cancer. More than 90 percent of pancreatic cancers harbor KRAS mutations, which can occur a decade or more before cancer develops.
In July, Johns Hopkins researchers reported that an experimental peptide vaccine targeting six common KRAS mutations elicited a significant immune response in 18 of 20 people at high risk of developing pancreatic cancer. The vaccine contains laboratory-made fragments of the abnormal proteins that these mutations produce, teaching the immune system to recognize and attack cells carrying them. Researchers detected vaccine-induced immune cells for as long as two years. While the small study cannot establish whether the vaccine prevents cancer, it raises the tantalizing prospect of training the immune system to eliminate precancerous cells before they develop into malignant tumors.
These developments should give politicians pause before passing judgment on entire fields of medical technology. Last year, Health and Human Services Secretary Robert F. Kennedy Jr. announced that his department would wind down 22 investments in mRNA vaccine development targeting infectious diseases. Whatever one thinks about taxpayer funding of medical research, politicians have limited ability to anticipate where a technology might lead or which of its applications might prove most valuable.
Personalized medicine poses an even more fundamental challenge to federal regulators.
For most of the pharmaceutical industry’s history, manufacturers have produced identical formulations of drugs for thousands or even millions of patients. Researchers test a formulation in clinical trials, and the FDA evaluates the results before permitting manufacturers to market it.
With personalized cancer vaccines, a pharmaceutical company might manufacture a thousand different formulations for a thousand different patients.
Regulators must evaluate how reliably manufacturers identify the appropriate genetic mutations, design the genetic instructions, manufacture individual doses, and ensure that each patient receives the correct vaccine. An October review in Frontiers in Immunology examined these and other challenges that personalized mRNA therapies pose for regulatory agencies.
The FDA already has some experience with individualized treatments. It has approved several chimeric antigen receptor (CAR) T-cell therapies, in which manufacturers genetically modify a patient’s own immune cells to attack cancer. But as scientists develop more ways to tailor treatments to individual patients, regulators will increasingly need to assess the reliability of the processes that produce medicines alongside the clinical evidence that those medicines work.
Why assume that a single government agency can keep abreast of all these rapidly evolving technologies better than multiple, independent organizations?
Competing certification organizations could develop expertise in different branches of personalized medicine, devise and refine evaluation methods as the science evolves, and provide physicians and patients with independent assessments of safety and effectiveness. Competition would allow different evaluation methods to emerge and improve as organizations learn from one another’s successes and mistakes. A regulatory monopoly makes everyone live with the consequences of the same mistakes.
Congress should end the FDA’s monopoly over drug approval and allow patients and their physicians to decide whose scientific assessments they trust and how much uncertainty they are willing to accept.
As medical innovation accelerates, the FDA will find it increasingly difficult to keep pace. Cancer patients may die while waiting for treatments that could have saved their lives.
Leave a comment